299 related articles for article (PubMed ID: 34089793)
1. Tagged extracellular vesicles with the RBD of the viral spike protein for delivery of antiviral agents against SARS-COV-2 infection.
Fu Y; Xiong S
J Control Release; 2021 Jul; 335():584-595. PubMed ID: 34089793
[TBL] [Abstract][Full Text] [Related]
2. Engineering Extracellular Vesicles Enriched with Palmitoylated ACE2 as COVID-19 Therapy.
Xie F; Su P; Pan T; Zhou X; Li H; Huang H; Wang A; Wang F; Huang J; Yan H; Zeng L; Zhang L; Zhou F
Adv Mater; 2021 Dec; 33(49):e2103471. PubMed ID: 34665481
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
Nayak SK
Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.
Tai W; He L; Zhang X; Pu J; Voronin D; Jiang S; Zhou Y; Du L
Cell Mol Immunol; 2020 Jun; 17(6):613-620. PubMed ID: 32203189
[TBL] [Abstract][Full Text] [Related]
5. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
Qiao B; Olvera de la Cruz M
ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
[TBL] [Abstract][Full Text] [Related]
6. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
[TBL] [Abstract][Full Text] [Related]
7. Potential chimeric peptides to block the SARS-CoV-2 spike receptor-binding domain.
Barh D; Tiwari S; Silva Andrade B; Giovanetti M; Almeida Costa E; Kumavath R; Ghosh P; Góes-Neto A; Carlos Junior Alcantara L; Azevedo V
F1000Res; 2020; 9():576. PubMed ID: 32802318
[No Abstract] [Full Text] [Related]
8. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
9. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
10. Genetically Engineered MRI-Trackable Extracellular Vesicles as SARS-CoV-2 Mimetics for Mapping ACE2 Binding
Galisova A; Zahradnik J; Allouche-Arnon H; Morandi MI; Abou Karam P; Fisler M; Avinoam O; Regev-Rudzki N; Schreiber G; Bar-Shir A
ACS Nano; 2022 Aug; 16(8):12276-12289. PubMed ID: 35921522
[TBL] [Abstract][Full Text] [Related]
11. Computational screening of 645 antiviral peptides against the receptor-binding domain of the spike protein in SARS-CoV-2.
Sakib MMH; Nishat AA; Islam MT; Raihan Uddin MA; Iqbal MS; Bin Hossen FF; Ahmed MI; Bashir MS; Hossain T; Tohura US; Saif SI; Jui NR; Alam M; Islam MA; Hasan MM; Sufian MA; Ali MA; Islam R; Hossain MA; Halim MA
Comput Biol Med; 2021 Sep; 136():104759. PubMed ID: 34403938
[TBL] [Abstract][Full Text] [Related]
12. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
[TBL] [Abstract][Full Text] [Related]
13. Potential therapeutic applications of extracellular vesicles in the immunopathogenesis of COVID-19.
Motallebnezhad M; Omraninava M; Esmaeili Gouvarchin Ghaleh H; Jonaidi-Jafari N; Hazrati A; Malekpour K; Bagheri Y; Izadi M; Ahmadi M
Pathol Res Pract; 2023 Jan; 241():154280. PubMed ID: 36580795
[TBL] [Abstract][Full Text] [Related]
14. Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles.
Wu C; Xu Q; Wang H; Tu B; Zeng J; Zhao P; Shi M; Qiu H; Huang Y
Acta Pharm Sin B; 2022 Mar; 12(3):1523-1533. PubMed ID: 34522576
[TBL] [Abstract][Full Text] [Related]
15. Sertraline Is an Effective SARS-CoV-2 Entry Inhibitor Targeting the Spike Protein.
Chen Y; Wu Y; Chen S; Zhan Q; Wu D; Yang C; He X; Qiu M; Zhang N; Li Z; Guo Y; Wen M; Lu L; Ma C; Guo J; Xu W; Li X; Li L; Jiang S; Pan X; Liu S; Tan S
J Virol; 2022 Dec; 96(24):e0124522. PubMed ID: 36468859
[TBL] [Abstract][Full Text] [Related]
16. Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates.
Kang YF; Sun C; Zhuang Z; Yuan RY; Zheng Q; Li JP; Zhou PP; Chen XC; Liu Z; Zhang X; Yu XH; Kong XW; Zhu QY; Zhong Q; Xu M; Zhong NS; Zeng YX; Feng GK; Ke C; Zhao JC; Zeng MS
ACS Nano; 2021 Feb; 15(2):2738-2752. PubMed ID: 33464829
[TBL] [Abstract][Full Text] [Related]
17. Identification of potential plant bioactive as SARS-CoV-2 Spike protein and human ACE2 fusion inhibitors.
Singh R; Bhardwaj VK; Sharma J; Kumar D; Purohit R
Comput Biol Med; 2021 Sep; 136():104631. PubMed ID: 34273770
[TBL] [Abstract][Full Text] [Related]
18.
Pandey AK; Verma S
Drug Dev Ind Pharm; 2022 Oct; 48(10):539-551. PubMed ID: 36250723
[TBL] [Abstract][Full Text] [Related]
19. Generation of Spike-Extracellular Vesicles (S-EVs) as a Tool to Mimic SARS-CoV-2 Interaction with Host Cells.
Verta R; Grange C; Skovronova R; Tanzi A; Peruzzi L; Deregibus MC; Camussi G; Bussolati B
Cells; 2022 Jan; 11(1):. PubMed ID: 35011708
[TBL] [Abstract][Full Text] [Related]
20. RBD-Modified Bacterial Vesicles Elicited Potential Protective Immunity against SARS-CoV-2.
Yang Z; Hua L; Yang M; Liu SQ; Shen J; Li W; Long Q; Bai H; Yang X; Ren Z; Zheng X; Sun W; Ye C; Li D; Zheng P; He J; Chen Y; Huang W; Peng X; Ma Y
Nano Lett; 2021 Jul; 21(14):5920-5930. PubMed ID: 34279108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
